Abstract
Breast cancer chemotherapy is marked by targeting the function of receptors such as ERα (estrogen receptor alpha), PR (progesterone receptor), EGFR (epidermal growth factor receptor), and CK2 (protein kinase receptor). In this study, the structures of ERα, PR, EGFR and CK2 were obtained from the protein data bank and docked with belinostat analogues using GOLD Suite 5.3 software. Combining both docking score and binding mode analysis criteria, some belinostat analogues exhibited as potential candidates to inhibit the function of breast cancer. The potential compounds are well-bound in their respective binding pose of the hormone receptors. This is mainly based on hydrogen bond interactions between the studied compounds and in-pose amino acids. Three compounds (C3, C5 and C8) gave the best results. Among them, compound C5 stood out as the best candidate for target CK2. This study suggested that N-hydroxycinnamamide can be further investigated and evaluated for breast cancer treatment.https://b.vjst.vn/index.php/ban_b/article/view/2378/1338
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
